Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis
- 25 March 2006
- journal article
- case report
- Published by Springer Nature in Clinical Rheumatology
- Vol. 26 (6) , 973-975
- https://doi.org/10.1007/s10067-006-0219-0
Abstract
Because disease activity in systemic lupus erythematosus correlates well with increased serum levels and activity of the cytokine tumor necrosis factor alpha (TNF-α), we report on the safety and efficacy of infliximab, a chimeric monoclonal antibody directed against TNF-α, given to a patient with active lupus with diffuse proliferative nephritis (WHO Class IV). This patient who failed to remit with a combination of full-dose steroids, mycophenolate mofetil, and cyclosporine, went into sustained remission with the addition of infliximab infusions.Keywords
This publication has 12 references indexed in Scilit:
- Induction of autoantibodies during prolonged treatment with infliximab.2003
- Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years.2001
- Tumor necrosis factor α blockers and the induction of anti-DNA autoantibodiesArthritis & Rheumatism, 2000
- Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trialsArthritis & Rheumatism, 2000
- Strong and Selective Glomerular Localization of CD134 Ligand and TNF Receptor-1 in Proliferative Lupus NephritisJournal of the American Society of Nephrology, 2000
- Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α Levels and Disease Acitivity in Systemic Lupus ErythematosusClinical Rheumatology, 1999
- Estimation of SLE Activity Based on the Serum Level of Chosen Cytokines and Superoxide Radical GenerationMediators of Inflammation, 1999
- Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity.1998
- TUMOUR NECROSIS FACTOR ALPHA AND ITS SOLUBLE RECEPTORS PARALLEL CLINICAL DISEASE AND AUTOIMMUNE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUSRheumatology, 1995
- Medical therapy for SLE.1991